Summary
Vertex Pharmaceuticals Incorporated (VRTX) has filed an 8-K report on February 12, 2026, announcing its consolidated financial results for the fourth quarter and full fiscal year ended December 31, 2025. While the specific financial figures are detailed in the press release (Exhibit 99.1), this filing serves as the official notification to the market of these results. Investors should refer to the press release for critical performance indicators, revenue streams, profitability, and any forward-looking statements or guidance provided by the company.
Key Highlights
- 1Vertex Pharmaceuticals reported its Q4 and full-year 2025 financial results on February 12, 2026.
- 2The financial results pertain to the period ending December 31, 2025.
- 3The press release containing detailed financial information is attached as Exhibit 99.1.
- 4This filing incorporates by reference the information provided in the press release.
- 5The report includes consolidated financial results for both the three and twelve months ended December 31, 2025.
- 6Investors are directed to Exhibit 99.1 for comprehensive financial details.